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Introduction: Obese women are predisposed to greater risks of insulin resistance and 
compensatory hyperinsulinemia. Likewise, African-Americans, appear to be inherently 
insulin resistant and hyperinsulinemic even after controlling for obesity. 
Hyperinsulinemia has been attributed to insulin resistance and a compensatory insulin 
hyper-secretion by the pancreas, as well as decreased insulin clearance, notably in 
obesity. Pharmacological agents that may worsen insulin resistance/hyperinsulinemia in 
obese women is of clinical relevance. Previous data from our group suggested that 
combined oral contraceptives (COCs) may worsen insulin sensitivity particularly in obese 
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women, but limited information on insulin clearance is available in obese women or 
African-American women.  
Objective: The objective of the study is to evaluate and compare the effect of a COC 
containing ethinyl estradiol and norgestimate on insulin clearance among lean and obese 
pre-menopausal women and among African-American obese vs. non African-American 
obese women. 
Method: Plasma insulin clearance was calculated from plasma insulin concentrations, 
following frequently sampled intravenous glucose tolerance test.   Changes in insulin 
clearance, during six months of COC use were analyzed by repeated measures analysis. 
Result: Six months of COC use showed no significant change in insulin clearance in all 
women (p=0.3713). Furthermore, there were no divergent effects on insulin clearance 
among lean (n=13) and obese (n=14) women (p=0.6703) and among African-American 
obese (n=7) and non African-American obese (n=7) women (p=0.0957). Changes in 
insulin clearance, following six months of COC administration was found to be positively 
correlated with changes in insulin sensitivity (r=0.385, p=0.0099) and negatively 
correlated with changes in acute insulin response to glucose (r=-0.432, p=0.0034). 
Discussion: In the present study, COC administration did not show any differential effect 
on insulin clearance in lean vs. obese women. Future studies evaluating the effects of 
hormonal agents on insulin-glucose dynamics may focus on mechanisms of hormone-
mediated insulin resistance and compensatory hyperinsulinemia rather than insulin 
clearance.  
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1. INTRODUCTION 
Obesity, defined as body mass index (BMI) ≥ 30 kg/m2 has assumed epidemic proportion, with 
over 32% of the adult population in the United States found to be obese (1). Sixty percent of  
adult women in particular are found to be overweight (BMI ≥ 25 kg/m2) (2).  
 
Obesity raises the risk of type 2 diabetes mellitus, dyslipidemia, and coronary heart disease. 
Interestingly, 80% of the subjects with type 2 diabetes mellitus are obese and insulin resistant 
(3).  
 
The major premise underpinning type 2 diabetes is insulin resistance (impaired insulin-mediated 
glucose uptake). Obesity has a significant role to play in the pathophysiology of insulin 
resistance (4) and consequent hyperinsulinemia (5). Obesity may accelerate insulin response by 
increasing β cell induced insulin secretion  and decreasing insulin clearance, especially in insulin 
resistant individuals (6). Hyperinsulinemia is found to be a strong predictor for insulin resistance 
syndrome, type 2 diabetes mellitus, hypertension, coronary artery disease, stroke and even cancer 
(4;7;8). Thus, worsening of insulin resistance and consequent hyperinsulinemia in obese women 
is of immense clinical relevance. 
 
Combined Oral Contraceptives (COCs) are the leading form of contraception in the United 
States (9) with over 11.6 million women receiving a prescription for it (10). Although COCs in 
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general do not worsen glucose tolerance (11), most studies evaluating the effect of COC on 
glucose metabolism have been performed in lean healthy women. 
 
COC may also alter insulin clearance and lead to hyperinsulinemia. One study suggested the 
possible role of progestin (norethindrone) in reducing insulin clearance, consequently leading to 
hyperinsulinemia (12). These findings were replicated in another study, which demonstrated 
significant decrease in insulin elimination during COC use containing norethindrone and 
desogestrel (13). Both studies were conducted in healthy lean women.  
 
Our research group has previously reported that insulin sensitivity is altered differentially 
depending on obesity status (14). Specifically, insulin sensitivity worsened with COC more so in 
obese women as compared with lean women. However, whether obesity status also affects 
COC’s alteration of insulin clearance is unknown. 
 
Hyperinsulinemia and abnormalities in hepatic insulin extraction has also been documented in 
ethnic groups with severe insulin resistance (15). Pathophysiologically, several studies have 
documented the greater prevalence of insulin resistance in the African-American population (16) 
in comparison to Caucasians. Studies have shown that the African-American group is inherently 
insulin resistant; displaying enhanced acute insulin response to glucose (AIRg) (17) and 
decreased insulin clearance in comparison to their Caucasian counterparts (18-21). Thus, a 
differential effect of COC on insulin clearance is also possible across ethnicity. 
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Hence, in the present study, we compared the effect of a low-dose cyclic COC containing ethinyl 
estradiol 35mcg and norgestimate 0.18/0.215/0.25 mg on insulin clearance in lean and obese pre-
menopausal women, after six months of COC use. In addition, we also performed a pilot analysis 
to evaluate the effect of insulin clearance in African-American obese women and non African-
American obese women. We also explored the relationship between changes in insulin clearance 
and changes in glucose-insulin dynamics following six months of COC use. 
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Specific Aims 
We hypothesize that exogenous administration of a low-dose COC is likely to decrease insulin 
clearance, more so in obese as compared to lean pre-menopausal women, and more so in 
African-American women as compared with Caucasian women. We tested our objective through 
the following specific aims: 
Specific Aim 1:  
Test the effect of a low-dose COC (containing ethinyl estradiol and norgestimate) on insulin 
clearance after six months of use in all pre-menopausal women. 
Specific Aim 2:  
Compare the effect of a low-dose COC (containing ethinyl estradiol and norgestimate) on insulin 
clearance after six months of use in lean and obese pre-menopausal women. 
Specific Aim 3: 
Perform a preliminary analysis to determine the effect of a low-dose COC (containing ethinyl 
estradiol and norgestimate) on insulin clearance after six months of use in African-American 
obese and non African-American obese pre-menopausal women. 
Specific Aim 4:  
To explore the relationship between changes in insulin clearance and changes in glucose-insulin 
dynamics, following six months of COC use. 
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2. BACKGROUND 
Obesity and Hyperinsulinemia 
The prevalence of obesity has doubled from 15% to 30% in the past three decades (2). In the 
United States, more than 60% of adult women are overweight (BMI ≥ 25 kg/m2). Obesity has 
been associated with conventional cardiovascular risk factors along with increase in 
inflammatory markers [high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor 
necrosis factor-α (TNF-α)], non-esterified fatty acids (NEFA), and coronary artery endothelial 
dysfunction (2). Obese women are pre-disposed to greater risks of type 2 diabetes mellitus and 
other cardiovascular complications. 
 
Obesity and insulin resistance/hyperinsulinemia are known risk factors for type 2 diabetes 
mellitus, cardiovascular diseases and hypertension (22). Also, obesity has been associated with 
insulin resistance and compensatory hyperinsulinemia (23).  
 
A number of putative mechanisms that underlie the temporal relationship between obesity and 
insulin resistance/hyperinsulinemia have been suggested. Some studies suggest that obesity 
precedes the clinical expression of insulin resistance/hyperinsulinemia (22). It is hypothesized 
that increase in body fat (esp. visceral fat) mobilizes the circulation of free fatty acids (FFAs) in 
portal vein circulation, thereby reducing the hepatic insulin clearance, thus contributing to 
peripheral hyperinsulinemia (24). Utilization of excess FFAs by muscles, at the expense of 
glucose may contribute to insulin resistance in obesity (25). Similarly, increased levels of NEFA, 
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as observed in obesity, also contributes to insulin resistance as a result of competition with 
glucose for substrate oxidation (26). Increased NEFA levels results in increased intracellular 
content of fatty acid metabolites like diacylglycerol (DAG), fatty acyl-coenzyme, and ceramide, 
which results in phosphorylation of insulin receptor substrate 1 and 2 (IRS1 and IRS2), leading 
to decreased activation of phosphatidyl inositol-3-OH kinase [PI(3)K]. Decreased signalling of 
PI(3)K induces hepatic gluconeogenesis and insulin resistance (26). A post-receptor defect has 
also been postulated with obesity. With increase in the adipose cell size, reduction in the insulin 
effect on glucose oxidation has been reported owing to decrease in the number of insulin 
receptors (24). Further, increased secretion of mediators of inflammation like IL-6, CRP, TNF-α 
by adipose tissue in obesity have also been linked with insulin resistance (22;26;27). Also, levels 
of adiponectin, an insulin-sensitizer, stimulating fatty acid oxidation is known to be lowered in 
obesity (26). 
 
Conversely, hyperinsulinemia may also contribute to obesity. Figure 1 shows an algorithm, 
describing the role of hyperinsulinemia in obesity. It is hypothesized that hyperinsulinemia 
interferes with leptin signal transduction in the hypothalamus, thereby promoting leptin 
resistance (28). Thus, the ability of leptin to stimulate α-melanocyte stimulating hormone and 
inhibit neuropeptide γ is hindered. This results in a decrease in resting energy expenditure (REE) 
and increase in appetite, promoting weight gain. In addition, hyperinsulinemia prevents 
dopamine reuptake at the nucleus accumbens, which promotes increased calorie intake (28).  
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Figure 1: Role of hyperinsulinemia in obesity 
 
Abbreviations: GLP-1- Glucagon like peptide 1; GIP- Gastric inhibitory polypeptide 
 
Various factors contribute to hyperinsulinemia, including vagus nerve induced insulin hyper- 
secretion, insulin resistance, and decreased insulin clearance (28). It is believed that 
hyperinsulinemia, insulin resistance and glucose stimulated insulin release are intertwined 
biologically (8). Hyperinsulinemia could result as a compensatory response to decreased insulin 
sensitivity. β-cells adapt to a chronic state of insulin resistance by secreting more insulin in 
response to a given plasma glucose levels (29). At the same time, hyperinsulinemia might itself 
perpetuate insulin resistance. Continuous exposure to insulin causes a reduction in the insulin 
receptor exposed on the cell surface, promoting internalization, followed by degradation (8). 
 
Savage et al conducted a study to evaluate if hyperinsulinemia associated with obesity was a 
result of reduced hepatic extraction or hyper-secretion of insulin by the pancreas.  In a study 
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conducted in normoglycemic, 10 Pima Indians and 10 Caucasians with varying degrees of 
obesity, the researchers found that the molar ratio of C-peptide to insulin was not significantly 
correlated with varying degree of obesity (r=0.08) (30). However, insulin and C-peptide 
concentrations were significantly correlated with degrees of obesity, with elevated levels of C-
peptide and insulin in obese subjects. These results indicate that hyperinsulinemia in obese 
subjects is a result of pancreatic hyper-secretion. Additionally, obesity may also affect insulin 
clearance. In a study by Meistas et al, total metabolic clearance of insulin was 33% lower in 
obese subjects than non-obese subjects (31). Hyperinsulinemia has also been closely linked to 
decreased hepatic insulin degradation in subjects with cirrhosis and liver dysfunction (32). These 
results underscore the fact that decreased hepatic insulin extraction could be a possible reason for 
hyperinsulinemia in obesity.  
 
African-American Race and Hyperinsulinemia 
Rising rates of obesity among African-Americans in comparison to Caucasians (33;34), along 
with a confluence of lifestyle-environmental and genetic factors, may have contributed to the 
greater prevalence of type 2 diabetes and concomitant cardiovascular complications in the 
African-American population (16). African-American women in particular showed 2 fold greater 
prevalence of type 2 diabetes in comparison to Caucasian women (35;36).  
 
However, lifestyle factors alone do not explain the disproportionately increased insulin resistance 
in African-Americans. Epidemiological studies have shown that African-Americans are 
significantly more insulin resistant and hyperinsulinemic than their Caucasian counterparts, even 
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after adjusting for body fat (20;35-38). In the Bogalusa Heart Study of 377 children (5-17 years), 
in comparison to Caucasian children, African-American children were found to have higher 
insulin response during oral glucose tolerance test (OGTT) and greater insulin to glucose ratio, 
suggestive of inherent insulin resistance (17). Hyperinsulinemia in African-Americans have been 
explained by hyper-secretion of insulin, as a compensatory response to decreased insulin 
sensitivity, and also by decreased insulin clearance (18-21;35;36;38), notably in obesity (36). 
Both lean and obese African-American pre-menopausal women were found to have significantly 
higher AIRg in comparison to their weight-matched Caucasian peers (36;37). In a study by Albu 
et al, a 163% significant increase in AIRg was noted in healthy African-American pre-
menopausal women when compared to Caucasian women (39). In another study, 14% lower 
insulin clearance and 63% higher first phase insulin secretion than Caucasian adolescents, 
accounted for hyperinsulinemia among African-American adolescents (38). One possible reason 
for decreased insulin clearance could be because of lower liver mass among African-Americans 
(20). In a study conducted in 22 healthy, pre-pubertal African-American and Caucasian children, 
African-American children were found to have 15% lower insulin clearance when compared 
with Caucasian children, even after adjusting for adiposity. Similarly, these results were 
replicated even in African-American adults (15;36).  
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Clinical Consequence of Hyperinsulinemia 
Clinical consequence of insulin resistance and compensatory hyperinsulinemia are increasingly 
appreciated for their role in type 2 diabetes mellitus and associated macro-vascular 
complications.  
 
Insulin resistance and consequent hyperinsulinemia precedes the clinical expression of type 2 
diabetes mellitus. Subjects with diabetes are 2-4 times more likely to have heart disease (40). 
Epidemiologic data have suggested that insulin resistance and consequent hyperinsulinemia is a 
risk factor for cardiovascular disease. Compared to normoinsulinemic, non-obese subjects; 
hyperinsulinemic, non-obese subjects with impaired glucose tolerance were associated with a 
cluster of cardiovascular risk factors such as elevated triglycerides, low levels of high density 
lipoprotein (HDL) and elevated systolic blood pressure (41). In the San Antonio Heart Study, 
hyperinsulinemia predicted the development of type 2 diabetes, low levels of HDL, high 
triglyceride levels, and hypertension over 8 years of follow-up (40;42). Additionally, in a meta-
analysis of 12 prospective based studies, insulin was found to be a positive indicator of 
cardiovascular disease, particularly in middle aged adults (40). The Quebec Cardiovascular 
Study and the Insulin Resistance Atherosclerotic Study (IRAS) also provides a strong association 
between insulin resistance/hyperinsulinemia and development of cardiovascular disease (40;42). 
In the IRAS study, a significant association was reported between insulin resistance and intima 
media thickness of the carotid artery. 
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Hyperinsulinemia has the potential to raise or maintain the blood pressure by promoting renal 
sodium absorption and stimulating the sympathetic nervous system (43). Also, the vasodilatatory 
action of insulin, owing to endothelial nitric oxide release, is reduced in obese subjects (43). 
Insulin resistance and consequent hyperinsulinemia is a strong predictor of coronary artery 
disease (4). Insulin resistance results in increased release of FFA into the circulation (7). Flux of 
FFA in the liver stimulates the secretion of very low density lipoprotein (VLDL), leading to 
hypertriglyceridemia. VLDL stimulates the exchange of cholesteryl esters (CE) from HDL and 
low density lipoprotein (LDL) for VLDL triglycerides (VLDL TG). Apolipoprotein A-I that 
dissociates from TG-enriched HDL, reduces the availability of HDL for reverse cholesterol 
transport. Also, TG-enriched LDL undergoes lipolysis to give rise to small, dense LDL. 
Culmination of low levels of HDL and the presence of small, dense LDL contribute to 
cardiovascular disease (7). Figure 2 provides a simplified model linking insulin resistance and 
cardiovascular disease. 
Figure 2: Model linking insulin resistance and cardiovascular disease 
 
Hyperinsulinemia may also directly inhibit fibrinolysis in obese, insulin resistant individuals (7). 
Visceral obesity is associated with increased levels of plasminogen activator inhibitor-I (PAI-I), 
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which complexes with plasminogen and eliminates its fibrinolytic activity (4). Hyper-
coagulability and impaired fibrinolysis in insulin resistant individuals add to the pathological 
basis for increased cardiovascular events (7). 
 
Combined Oral Contraceptives and Glucose-Insulin Metabolism 
COCs are the most common form of contraception, with over 100 million women using it 
worldwide (10). In the US alone, 11.6 million women are COC users (10). In fact, 4 of the top 
200 prescribed drugs in the US comprise of COCs.  
 
Studies have substantiated the ability of COC to impair glucose tolerance within six months of 
use (12;13;44-46). In one of the earlier studies, Doar et al studied the effects of COC use and 
obesity on plasma glucose and pyruvate levels. In comparison to non-obese subjects, obese 
subjects were found to have significantly higher blood glucose and pyruvate levels (47). 
However, it was a cross-sectional study, providing little information on different indices of 
glucose metabolism.  
 
Exogenous estrogens may have different effects on carbohydrate metabolism based on doses 
used (48). In comparison to higher doses, lower dose COC are known to produce fewer side 
effects (49). Administration of exogenous low concentration (10X) of 17 β estradiol 
(dose=0.326µg/day) in ovariectomized rats was found to up-regulate IRS-1, subsequently 
increasing the insulin sensitivity in muscle and adipose tissue (50). However, high concentration 
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(100X) of 17 β estradiol (dose=0.326µg/day) was found to produce an opposite effect (50). 
High-dose COC (ethinyl estradiol- EE >50 µg + progestin) use in particular resulted in the 
development of impaired glucose tolerance in 15.4% of current COC users (n=354) versus 6.3% 
of non-COC users (n=1732) (44). In women with diabetes mellitus, administration of high-dose 
COC resulted in further worsening of glucose metabolism in 73% of the users (44). In women 
with previous gestational diabetes, high-dose COC (0.08 mg mestranol) use resulted in the 
development of impaired glucose tolerance in 2 of 12 subjects, along with deterioration in 4 of 
12 subjects in a period of 2 weeks. Integrated insulin response to glucose, though delayed, was 
also found to increase by 2 fold (51). Additionally, in a cross-sectional study conducted in 
women on COC containing 0.1mg mestranol + 2mg norethindrone (high-dose) for a period of 
9.5 years, 12 out of 31 subjects were found to have abnormal glucose tolerance (46). Marginally 
reducing the dose and duration of COC use (sequential type COC containing 0.08mg mestranol + 
2mg chlormadinone acetate for a period of 6.5 years) resulted in only 1 out of 31 women with 
abnormal glucose tolerance (46). These results substantiate the deleterious effects of high-dose 
COC on glucose metabolism. Thus, a transition from high-dose to low-dose COC use was made 
in clinical practice. A recent Cochrane analysis suggested that low-dose COC (EE ≤ 35 µg) may 
have limited effects on glucose metabolism in normal weight women (11).  However, a few 
studies have shown that even low-dose COC, with estrane (norethindrone) and gonane 
(levonorgestrel, norgestrel) progestins, are associated with impaired glucose homeostasis 
(44;45). In a study by Wynn, 210 women who initiated COC (EE 30 µg + levonorgestrel 150 µg) 
were prospectively followed for a period of 3 years. At the end of 3 months, 13% of the subjects 
were found to be glucose intolerant. While at 15
th
, 25
th
 and 37
th
 months, the number of glucose 
intolerant subjects were found to increase to 10%, 20% and 30% respectively (46). Similarly, in 
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a cross-sectional study, low-dose Lovral® (EE 30 µg + norgestrel) users also showed lowered 
insulin sensitivity and glucose effectiveness (ability of glucose to promote its uptake at basal 
insulin levels) in comparison to control users (never used or discontinued COC use in the past 24 
months) (45). Hence, although the recent Cochrane analysis showed that low-dose COC use had 
little effect on glucose metabolism in healthy lean women with no known risk of diabetes (11), 
evidence exist that the risk is present. Importantly, we have limited information regarding obese 
women (11). 
 
Effect of low-dose COC on glucose metabolism also depends on the type of progestins. 
Progestins have been shown to antagonize the effect of insulin on glucose metabolism in adipose 
tissue and skeletal muscle, by bringing about a decrease in the target tissue insulin receptor 
number and affinity (49). Gonane progestins (levonorgestrel, norgestrel) in particular may 
elevate blood glucose and insulin levels (11;44). On the other hand, newer progestins such as 
desogestrel and drospirenone were found to have a limited effect on carbohydrate metabolism, 
when used for 1 year (44;52). COC’s progestin component’s effects on carbohydrate metabolism 
has been attributed to their androgenic activity (46;48). Low androgenic hormonal contraceptives 
(e.g. containing medroxy progesterone acetate) were associated with reduced risk of gestational 
diabetes mellitus (Odds Ratio=0.84, 95% CI 0.58-1.22), in comparison to high androgenic 
contraceptives like levonorgestrel (Odds Ratio=1.43, 95% CI 0.92-2.22) (53). In a study 
comparing the effects of COC with the progestin drospirenone (17-α spirolactone derivative, 
with anti-androgenic property) and desogestrel on glucose metabolism, no significant changes in 
fasting glucose and insulin levels were observed at the end of cycle 6 and 13, in both the 
treatment groups. The mean area under the curve-AUC (0-3 hr) for glucose moderately increased 
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by 28.7 mg/dL*h in the drospirenone group and by 22.2 mg/dL*h in the desogestrel group. 
Modest increase in mean insulin levels was also observed. But none of these effects were 
significant (52). Norgestimate, the proposed progestin in our study has little adverse effects on 
carbohydrate metabolism. In a study by Burkman et al, no significant changes in fasting blood 
glucose, insulin or glycosylated hemoglobin levels were observed at the end of 2 years of COC 
use containing norgestimate (54). 
 
Studies have also suggested that the progestin component may prolong insulin half life and 
decrease insulin clearance (12;55;56). In a study evaluating the effect of COC (combined 
formulations of 30-40 µg EE with triphasic regimen of levonorgestrel and monophasic regimen 
of desogestrel and norethindrone) on glucose metabolism in healthy Caucasian women, the 
researchers found that the desogestrel combination significantly decreased the insulin elimination 
constant in comparison to non-COC users (13). The mean insulin half-life was found to be 5.06 
minutes in non-COC users and 6.48 minutes in desogestrel combination users (13). Similar 
effects have also been demonstrated by norethindrone-type preparations. Addition of 
norethindrone 1mg to ethinyl estradiol was found to significantly decrease the rate constant for 
insulin disappearance, when compared to ethinyl estradiol alone (9.97 ± 0.25%/min vs. 9.39 ± 
0.22%/min, p <0.03) (12). These results suggest the possibility that the progestin component may 
decrease insulin clearance, and thereby prolonging its circulation.  
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Knowledge Gap 
Previous studies have suggested that hyperinsulinemia could be a result of compensatory 
increased secretion of insulin, due to insulin resistance or due to decreased insulin clearance, 
notably in obesity (35;36;57). Our research group has previously conducted a study to determine 
if there was a differential effect of COC on insulin sensitivity, depending on obesity status. The 
study found divergent effects of COC on insulin sensitivity in lean vs. obese women, with obese 
women displaying lowered insulin sensitivity (14). Six months of COC use worsened insulin 
sensitivity in obese women, with no significant change in AIRg. If insulin sensitivity and AIRg 
are related by a hyperbolic curve (58), then reduction in insulin sensitivity in obese subjects 
would have been compensated by increased AIRg. However, in the aforementioned study by our 
research group, no change in AIRg was observed with COC use. This postulated the possibility 
of decreased insulin clearance, contributing to hyperinsulinemia, with COC use. Hence, the 
objective of the study was to determine if insulin clearance is different in obese vs. lean pre-
menopausal women after COC use.  
 
Numerous studies have suggested that African-Americans have a greater degree of obesity and 
are predisposed to insulin resistance/hyperinsulinemia and consequent type 2 diabetes mellitus 
and cardiovascular complications, in comparison to their Caucasian counterparts (18-
20;35;36;38;39;59;60). Hence, we also tested the effect of COC on insulin clearance in African-
American obese vs. non African-American obese pre-menopausal women. 
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Significance 
Obese women are at a greater risk of insulin resistance and hyperinsulinemia (23;25-27). 
Hyperinsulinemia has been associated with insulin resistance syndrome, hypertension, coronary 
artery disease, and coagulation abnormalities (4). Hyperinsulinemia can result from insulin 
resistance or decreased insulin clearance. Although COC’s effect on glucose metabolism and 
insulin resistance in lean women are well known, data on obese women are sparse. This is a 
critical knowledge gap, as obese women are already at a greater risk of insulin resistance and 
hyperinsulinemia, and further worsening of this condition is of clinical relevance to these 
women. The specific objective of this study is to evaluate the effect of a low-dose COC 
(containing ethinyl estradiol and norgestimate) on insulin clearance in lean and obese pre-
menopausal women. Furthermore, we tested if the difference in insulin clearance differed across 
African-American obese and non African-American obese women, owing to greater prevalence 
of obesity, insulin resistance/hyperinsulinemia in this population (34-36).  
 
The proposed study is innovative because no study to date has prospectively compared the effect 
of COC on insulin clearance in lean and obese pre-menopausal women. This contribution is 
significant because it is a step towards a continuum of research in deciphering the processes 
underlying impairment of glucose metabolism in obese women upon COC use. 
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3. METHODS 
Study Design 
Our analysis of insulin clearance data was performed using data from a previously conducted 
prospective single center trial, evaluating 13 lean (control group) and 14 obese pre-menopausal 
women over a period of six months (14).  In this study, we evaluated the effect of a low-dose 
COC (containing ethinyl estradiol and norgestimate) on glucose-insulin homeostasis. Details of 
this previous study are provided below along with the methodology used for the estimation of 
insulin clearance in the current study. 
 
Intervention 
COC containing ethinyl estradiol 35 mcg and norgestimate 0.18/0.215/0.25 mg (Ortho Tri-
Cyclen®, Ortho-McNeil Pharmaceutical). This COC is one of the most widely prescribed COC 
in the United States (9). 
 
Study Population 
Participants were deemed eligible in the study provided they met the following inclusion 
criteria: (i) Pre-menopausal women, 18 to 40 years of age, (ii) lean women with BMI < 25 
kg/m
2
 and obese women with BMI ≥ 30 kg/m2, (iii) with no COC use within past three months 
of the study, (iv) expressing willingness and providing an informed consent to take part in the 
study, (v) and expressing their ability to comply with the study requirements. The following were 
the exclusion criteria: (i) presence of diabetes mellitus, assessed by OGTT (fasting glucose ≥ 
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126mg/dl or a 2 hour glucose ≥ 200mg/dl), (ii) systolic blood pressure > 160mmHg or diastolic 
blood pressure > 100mmHg, (iii) presence of any pulmonary, cardiac (history of 
thromboembolism, myocardial infarction, cerebrovascular accident, vascular disease or known 
coagulopathy), renal, hepatic, neurological (including migraine, headaches), psychiatric, 
infectious and malignant diseases, (iv) use of any hypoglycemic, gluco-corticoids, anti-
androgens (e.g. spironolactone, flutamide), anti-hypertensive, lipid lowering agents that are 
known to affect the glucose metabolism, (v) prolonged immobilization, or major surgery within 
past six months, (vi) use of any investigational drugs within three months, (vii)  pregnant or 
lactating women, (viii) anemic women (hematocrit < 33%), (viii) smoker ≥ 20 cigarettes/day, 
and (ix) subjects actively attempting weight loss. 
 
Recruitment 
Subjects were recruited from the student health clinics and obstetrics/gynecology centers at 
Virginia Commonwealth University Medical center via poster, fliers in and around the campus. 
The study was conducted at the General Clinical Research Center (GCRC).  
 
Potential subjects were then enrolled into the study only after obtaining an informed consent. 
Participants visited the GCRC for study procedures at baseline, and after three and six months of 
COC administration. 
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The study was approved by the Institutional Review Board (IRB) at Virginia Commonwealth 
University. 
 
Study Protocol 
Recruited participants presented to the GCRC after a 12-hour overnight fast during the follicular 
phase of their menstrual cycle (confirmed by a serum progesterone level of <2ng/ml). On day 1, 
an OGTT with 75 gm of glucose was performed. On day 2, participants underwent the modified 
frequently sampled intravenous glucose tolerance test (FSIVGTT), as described by Bergman 
(61). At time 0, 300mg/kg glucose solution was administered intravenously as a bolus over 1 
minute, followed by 0.03U/kg insulin infusion at 20 minutes. Blood was then drawn at -15, -5, 0, 
2, 3, 4, 5, 6, 8,10, 12, 14, 16, 19, 22, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 140, 160, and 
180 minutes (61;62).  
 
Participants were then started on a COC [Ortho Tri Cyclen; containing ethinyl estradiol 35mcg 
and norgestimate0.18/ 0.215/0.25 mg for a period of six months]. All participants were instructed 
to take the active pill everyday for 21 days, followed by a 7 day pill free period. Participants 
were also instructed to maintain their normal dietary and physical activity during the six month 
period. 
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Follow up 
A first follow up was scheduled three months from COC use, between 5
th
 and 7
th
 day of the 
hormone-free week, to minimize the effect by progestins on insulin kinetics. A repeated 
assessment of the 2-hr OGTT was performed. A second follow up visit was scheduled six 
months from baseline, between 5
th
 and 7
th
 day of the hormone-free week. On days 1 and 2 of the 
six month follow up visit, study procedures were the same as days 1 and 2 of the baseline visit.  
 
Methodology 
All samples to be analyzed were stored at -70⁰C. Glucose was analyzed by glucose oxidase 
methodology (YSI 2300 Stat Plus Glucose Analyzer, Yellow Spring Instruments (YSI), Yellow 
Springs, OH), while plasma insulin was analyzed using ELISA (ALPCO Diagnostics, Salem, 
NH). All samples were analyzed in duplicates. 
 
Measurement of insulin clearance: 
 
Plasma insulin clearance was estimated from plasma insulin measurements from FSIVGTT, 
taken after exogenous administration of insulin bolus infusion, assuming a single compartment 
model.  
 
Plasma insulin concentration declines following administration of intravenous infusion of insulin 
at 20 minutes. Figure 3 provides a description of how plasma insulin concentration diminishes 
following intravenous insulin administration at 20 minutes. However, plasma insulin level 
stabilizes and attains a steady state around 50-60 minutes. 
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Figure 3: Plasma insulin-glucose concentrations, following FSIVGTT 
 
 
Steady state insulin concentration (Iss) was calculated by taking an average of the plasma insulin 
levels after it stabilizes. The difference between insulin measurements (from peak insulin 
concentration following insulin bolus infusion to steady state insulin concentration) is I-Iss. 
Figure 4 provides a graph of I-Iss in a woman with a BMI of 24kg/m
2
. 
 
Figure 4: I-Iss 
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Insulin elimination constant (Ke, min
-1
) was determined by the negative slope of the regression 
of the logarithm (I-Iss) against time (i.e. time from peak insulin concentration following insulin 
infusion to steady state insulin concentration) multiplied by 2.303.  
 
Volume of distribution (Vd, L) was calculated using the formula: 
Vd= dose/C0; 
 
Where dose was the amount of insulin infusion per kg body weight and C0 was the predicted 
plasma insulin concentration (I-Iss) at 20 minutes.  
 
 Figure 5 provides a graph of both (I-Iss) and predicted (I-Iss) for the same woman as described 
above.  
 
Figure 5: (I-Iss) and predicted (I-Iss) 
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Finally, total insulin clearance (CLtot, L/min) was calculated using the formula (63): 
CLtot= Vd * Ke 
 
Measurement of glucose-insulin dynamics: 
 
Glucose-insulin dynamics was calculated from modified FSIVGTT, using the Minimal Model 
Identification Software (MINIMOD), version 6.02, Los Angeles, CA) (64). The aforementioned 
software is a robust, accurate, reproducible and user friendly software for measuring the glucose-
insulin dynamics. Insulin sensitivity measured by this method indicates the net capacity of 
insulin to promote peripheral and hepatic glucose uptake and also inhibit endogenous glucose 
production. Insulin sensitivity index (Si) is calculated using the formula; Si=P3/P2 (where P3 is a 
parameter describing the levels of circulating insulin in interstitial fluid and P2 is a parameter 
describing the removal rate of insulin from interstitial fluid) (61;64). The minimal model also 
provides estimation of glucose effectiveness (Sg), AIRg (area under the plasma insulin curve 
between 0 and 10 minutes, which is a measure of first phase insulin secretion), and disposition 
index (DI, which is Si * AIRg, composite measure of insulin secretion and action) (64).  
 
Insulin and glucose incremental area-under-the-curve (AUC) upon OGTT was analyzed by the 
trapezoidal rule after subtracting baseline values. Glucose-insulin values from OGTT was also 
used to calculate the Matsuda insulin sensitivity index (65), using the following formula: 
[10,000/ √ {(fasting plasma glucose * fasting plasma insulin) * (mean OGTT glucose 
concentration * mean OGTT insulin concentration)}]. Homeostasis model assessment or HOMA 
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uses a computer solved model to estimate insulin sensitivity and β cell function using the basal 
steady state plasma glucose and insulin levels, given by the formula:  
HOMA-Insulin Sensitivity Index=405/ [Fasting glucose (mg/dl) * Fasting insulin] (61;66).  
 
Data Analyses 
JMP 8 statistical software (SAS Institute Inc., Cary, NC) was used to perform all the analysis 
using a significance level of 0.05. The primary outcome of interest was the mean change in 
insulin clearance from baseline after six months of COC administration, among obese vs. lean 
pre-menopausal women. Additionally, mean change in insulin clearance was also assessed 
among African-American obese vs. non African-American obese pre-menopausal women. We 
also looked into the overall effect of COC use on insulin clearance in all women regardless of 
baseline obesity status after six months of COC administration. Relationship between changes in 
insulin clearance with six months of COC use and changes in glucose-insulin indices was also 
evaluated. 
 
Normality distribution was confirmed. All continuous variables were described using mean and 
standard deviation, while categorical variables were described using counts and proportion. 
Baseline comparisons between lean and obese women were performed using students’ t-test in 
case of equal variance, while Welch ANOVA was used if unequal variance was observed. 
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Our primary research question, i.e. mean change in insulin clearance from baseline after six 
months of COC use, among lean and obese pre-menopausal women was tested by repeated 
measure analysis. The model consisted of insulin clearance as the outcome variable; subject ID 
as a random effect, time trend, obesity status along with their interaction with time trend as fixed 
effects. Similarly, mean change in insulin clearance from baseline after six months of COC use 
in African-American obese and non African-American obese women was tested by repeated 
measure analysis. Change in insulin clearance from baseline to six months in all women 
regardless of obesity status was analyzed by paired t-test. Also, change in insulin clearance 
within each of the group (lean, obese, African-American obese and non African-American 
obese) was assessed by matched paired t-test. 
 
Relationship between changes in insulin clearance and changes in glucose-insulin dynamics, 
following six months of COC use was evaluated by a simple correlation test. 
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4. RESULTS 
Baseline Characteristics 
A total of 48 pre-menopausal women provided their informed consent for the study. However, 
only 27 women completed the entire course of the trial, with 4 no-shows, 4 failing to meet the 
screening-eligibility criteria, 5 losses to follow up and 8 withdrawing from the study. Table 1 
provides the distribution of body type and race in the analyzed (n=27) and the unanalyzed (n=21) 
group. 
Table 1: Distribution of body type and race in the analyzed and unanalyzed group 
PARAMETER GROUP  
 Analyzed 
(n=27) 
Unanalyzed 
(n=21) 
P-value 
Body Type  Lean    (BMI < 
25kg/m
2
) 
13 (48.15%) 2 (9.5%) <0.0001* 
Obese (BMI ≥ 
30kg/m
2
) 
14 (51.85%) 7 (33.33%) 0.0018* 
Information 
Unavailable 
- 12 (57.14%) - 
Race African-
American 
8 (29.63%) 4 (19.05%) 0.0185* 
Caucasian 17 (62.96%) 8 (38.1%) 0.0002* 
Hispanic 2 (7.4%) 0 - 
Asian 0 2 (9.52%) - 
Information 
Unavailable 
- 7 (33.33%) - 
*Indicates significant difference (p<0.05) 
 
The 27 women included in the study consisted of lean (n=13) and obese (n=14) women (see 
Table 2). Seven of the 14 obese women were African-Americans, while the other seven were 
Caucasians (table 3).  
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Table 2: Proportion of lean and obese women 
Group   N Proportion 
Lean  13 0.481 
Obese  14 0.518 
 
 
Table 3: Proportion of African-American obese women 
Group  N Proportion 
Non African-American obese women 7 0.500 
African-American obese women 7 0.500 
 
At baseline, ages of the lean and obese women in the study were similar. As predicted, obese 
women had significantly higher BMI, systolic-diastolic blood pressure (BP), waist circumference 
and waist-hip-ratio. Baseline demographic characteristics of the study subjects are summarized 
in table 4. 
Table 4: Baseline demographic characteristics of study subjects 
Parameter Lean women (n=13)  Obese women (n=14)  P value 
Age (yrs) 21.23 ± 2.31  22.5 ± 5.24  0.4300 
BMI (Kg/m
2
) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Waist Circumference 
(cm) 
Waist-Hip-Ratio 
20.99 ± 1.57 
105.97 ± 9.31 
68.28 ± 3.86 
67.85 ± 8.39 
 
0.705 ± 0.08 
 
 
 
 
 
 
36.93 ± 6.75 
121.71 ± 13.83 
74.05 ± 8.67 
99.56 ± 13.95 
 
0.787 ± 0.057 
 
 
 
 
 
 
<0.0001 * 
0.0020 * 
0.0364 * 
<0.0001 * 
 
0.0051 * 
*Indicates significant difference (p<0.05) 
Mean ± standard deviation 
 
Baseline comparison of glucose-insulin dynamics showed that obese women were less insulin 
sensitive than lean women. Using the minimal model, we found that obese women had 
significantly lower insulin sensitivity (difference= -3.28 units, S.E= 1.10, 95% CI= -5.56 to -
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1.00) than lean women (t= -2.97, df= 24, p= 0.0066). Significantly lower insulin sensitivity in 
obese women was also demonstrated by HOMA (t= -3.245, df= 25, p= 0.0033) and Matsuda 
indices (t= -2.641, df= 25, p= 0.0149).  The results are summarized in table 5. 
 
Low insulin sensitivity in obese women was compensated by hyper-secretion of insulin by the 
pancreas. Obese women had significantly higher AIRg (t= 4.378, df= 18.295, p= 0.0004) in 
comparison to their lean counterparts. No significant difference in insulin clearance was 
observed between the two groups at baseline (table 7). 
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Table 5: Baseline comparison of glucose-insulin dynamics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Least square mean ± standard error    
*indicates significant 
 
 
Parameter Lean women (n=13) Obese women (n=14) P value  
 Baseline Baseline  
AIRg[mu.L
-1
 .min] 
 
Si[min
-1
/mu/L] 
 
Incremental AUC glucose 
 
Incremental AUC insulin  
 
Sg (1000.min
-1
) 
 
DI (AIRg.Si) 
 
ISI HOMA 
 
Matsuda index 
324.84 ± 93.69 
 
7.19 ± 0.823 
 
3080.6 ± 590.97 
 
3905.9 ± 622.89 
 
0.037 ± 0.0058 
 
2161.35 ± 444.33 
 
1.56 ± 0.215 
 
11.74 ± 1.35 
 
840.38 ± 92.36  
 
3.85 ± 0.812 
 
2732.4 ± 569.47 
 
4400.84 ± 600.23 
 
0.028 ±  0.0058 
 
3126.74 ± 439.35 
 
0.92 ± 0.207 
 
7.22 ± 1.3 
0.0004 * 
 
0.0066 * 
 
0.6622 
 
0.6151 
 
0.4186 
 
0.1352 
 
0.0033 * 
 
0.0149 * 
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Specific Aim 1: Effect of COC on insulin clearance in all women 
Six months of COC use did not have any significant effect on insulin clearance when all the 27 
women were analyzed together. The results are summarized in table 6. 
Table 6: Effect of COC on insulin clearance in all women 
Insulin clearance 
(l/min) 
 Baseline  6 months Difference (6 
months-
baseline) 
 P value 
  1.11 ± 0.078  1.2 ± 0.078 0.09 ± 0.099 
(95% CI= -
0.115 to 0.296) 
 0.3713 
Least square mean ± standard error 
 
Specific Aim 2: Effect of COC use on insulin clearance in lean vs. obese women 
No significant difference in insulin clearance was observed after six months of COC use, based 
on obesity status, as summarized in table 7. Within each of the group (i.e. lean and obese group), 
no significant difference in insulin clearance was observed with six months of COC use.  
Even after adjusting the insulin clearance for body weight, no significant difference [F (1, 25) = 
0.067, p=0.7978] in insulin clearance was observed after six months of COC use between lean 
and obese women. 
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Table 7: Effect of COC on insulin clearance in lean vs. obese women 
Parameter Lean women 
(n=13) 
Obese women 
(n=14) 
P value 
(baseline 
comparison 
between 
groups) 
P value 
(comparison of 
COC effects 
between 
groups) 
 Baseline 6 
months 
Baseline 6 
months 
  
Insulin 
clearance 
(l/min) 
1.22 ± 
0.113 
1.27 ± 
0.113 
1.01 ± 
0.109  
1.15 ± 
0.109 
0.1368 0.6703 
P value  
(paired t-
test) 
0.7893 0.2884 
Least square mean ± standard error 
 
Specific Aim 3: Effect of COC on insulin clearance in African-American obese vs. non 
African-American obese women 
At baseline, there was no significant difference in insulin clearance between African-American 
obese vs. non African-American obese women (Table 8). Six months of COC use resulted in no 
significant effect on insulin clearance between the two groups. No significant change in insulin 
clearance was also observed within each of African-American obese and non African-American 
obese women group.  
 
 
 
 
 
 
33 
 
Table 8: Effect of COC on insulin clearance in African-American obese vs. non African-
American obese women 
Parameter African- American 
obese women 
(n=7) 
Non-African-
American obese  
women (n=7) 
P value 
(baseline 
comparison 
between 
groups) 
P value 
(comparison of 
COC effects 
between 
groups) 
 Baseline 6 
months 
Baseline 6 
months 
  
Insulin 
clearance 
(l/min) 
0.963 ± 
0.129 
0.895 ± 
0.129 
1.07 ± 
0.129  
1.4 ± 
0.129 
0.5184 0.0957 
P value  
(paired t-
test) 
0.2816 0.1706 
Least square mean ± standard error 
 
 
Specific Aim 4: Relationship between changes in insulin clearance and changes in glucose-
insulin dynamics with COC use (taking all the women into consideration) 
Changes in insulin clearance with six months of COC was found to be significantly related to 
changes in AIRg, insulin sensitivity as measured by minimal model, incremental AUC glucose 
and glucose effectiveness (Table 9). Changes in insulin clearance was positively related with 
changes in insulin sensitivity (figure 6) and negatively related with changes in AIRg (figure 7). 
However, no significant relationship was observed between changes in insulin clearance and 
changes in incremental AUC glucose, disposition index, and insulin sensitivity measured by 
HOMA and Matsuda index. 
 
 
 
 
34 
 
Table 9: Relationship between changes in insulin clearance and changes in glucose-insulin 
dynamics after six months of COC use 
 Insulin clearance (l/min) 
Parameter  Correlation (r) P value 
AIRg 
[mu.L
-1
 .min] 
-0.432 0.0034 * 
Si 
[min
-1
/mu/L] 
 
0.385 0.0099 * 
Incremental AUC glucose 
 
0.4257 0.0040 * 
Incremental AUC insulin 
 
0.1298 0.401 
Sg (1000.min-1) 
 
0.484 0.0009 * 
DI (AIRg.Si) 
 
-0.029 0.8503 
ISI HOMA 
 
0.225 0.1413 
Matsuda index 
 
0.120 0.4363 
*indicates significant 
 
Figure 6: Scatter plot showing the relationship between changes in insulin clearance and 
changes in insulin sensitivity following six months of COC use 
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Figure 7: Scatter plot showing the relationship between changes in insulin clearance and 
changes in AIRg following six months of COC use 
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5. DISCUSSION 
Obesity has been correlated with hyperinsulinemia, and this effect is attributed to both 
compensatory hyper-secretion of insulin by the pancreas secondary to insulin resistance and 
decreased insulin clearance.  In a previous study, we have reported the effects of COC on insulin 
sensitivity in lean and obese women (14).  Six months of COC use showed divergent effects on 
insulin sensitivity in lean vs. obese women, as measured by the minimal model (p=0.0494). 
These effects were also demonstrated by other measures of insulin sensitivity, such as the 
Matsuda index (p=0.0227) and ISI HOMA (p=0.0128). In the above mentioned study, following 
six months of COC administration, insulin sensitivity worsened in obese women and improved in 
lean women. No significant difference was observed between lean and obese women in changes 
in AIRg during six months of COC use (14). Considering the worsening of insulin sensitivity and 
no change in AIRg in obese women, we were interested to see if insulin clearance had a role to 
play in contributing to hyperinsulinemia. Hence, in this study, we set out to examine whether a 
commonly used COC affect insulin clearance, and whether effects on insulin clearance is 
different between lean and obese women. 
 
Insulin clearance involves both first-pass hepatic elimination (30) and peripheral insulin uptake, 
internalization and degradation. At physiological concentration (10
-9
 M), insulin uptake is a 
receptor mediated process, while at non-physiological concentration, non-receptor mediated 
processes predominates (67). Liver contributes to about 50-70% of insulin degradation (29), 
while kidney is the main site for insulin clearance from the systemic circulation (67). Other sites 
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of insulin uptake and degradation comprises of pancreas, adrenal gland, testis, spleen, ovary, 
lung, heart, muscles, brain and fat. 
 
In the present study, there was no differential effect on insulin clearance in lean vs. obese 
women, after six months of COC administration. One of the possible reasons for this could be 
because of our choice of progestin. We based our choice of COC (ethinyl estradiol 35 mcg and 
norgestimate 0.18/0.215/0.25 mg) used in the study on agents that are most commonly used. 
Although we reported a differential effect of norgestimate-containing COC on insulin sensitivity 
in lean vs. obese women in a previous study (14), other studies have shown a metabolic neutral 
effect. Norgestimate, a 3
rd
 generation gonane progestin is known to have minimal metabolic 
effects (54;68-72). It also has a low androgenic profile (70). Use of a norgestimate-containing 
oral contraceptive for a period of 2 years among healthy women was not associated with 
clinically significant changes in fasting plasma glucose or insulin levels (54). Only 2% of the 
women on norgestimate-containing COC developed abnormal fasting glucose levels after six 
months of use, while 35% lowered their initial abnormal glucose levels into the normal range 
after six months of use (71). Additionally, norgestimate containing COC have also shown 
favorable effect on lipid profile, including elevation of HDL, reduction of LDL and improved 
HDL/LDL ratio (69;71). These results suggest that norgestimate containing COC show minimal 
effect on glucose-insulin dynamics. 
 
No differential effect on insulin clearance was also observed between African-American obese 
(n=7) vs. non African-American obese (n=7) women after six months of COC use. It is 
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interesting to note that even in a small sample size of 7 in each group; the effect reached a 
significance level of 0.0957, suggesting that it may be worthwhile to repeat this study in a larger 
cohort. 
 
Changes in insulin clearance with six months of COC use was found to have a negative 
relationship with changes in AIRg and a positive relationship with changes in insulin sensitivity, 
as measured by the minimal model.  Causations cannot be established with this study.  Limited 
information exists regarding the association between hyperinsulinemia and decreased insulin 
clearance.  It is also possible that with a higher AIRg, pancreatic insulin secretion may continue 
while insulin is being cleared, resulting in a net reduced insulin clearance.  
 
In the present study, total insulin clearance was quantified from insulin concentration obtained 
during FSIVGTT test. It is reported that the plasma insulin concentration declines following 
intravenous insulin infusion, with at least two exponential decay (63).  Hence, steady state 
insulin concentration was used to determine the total insulin clearance. Total clearance was 
obtained by the product of insulin elimination constant and volume of distribution (Vd= 
Dose/C0), with dose of insulin infusion adjusted to body weight of each individual. However, 
some methodological inadequacies are present in this study. Insulin degradation is described as 
linear first order kinetics, considering the narrow concentration intervals. This could be a 
possible limitation of the study as some amount of non-linearity has been demonstrated owing to 
saturable processes (73). The given study does not provide a measure of endogenous insulin 
production and its subsequent clearance. In the case of exogenous insulin infusion, endogenous 
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insulin secretion is suppressed by somatostatin (29). Under this condition, insulin clearance by 
the liver and peripheral tissue occurs in parallel. Metabolic clearance (MCR) of endogenous and 
exogenous insulin is related by the following formula: (29) 
 
MCRendogenous= MCRexogenous / (1-Eh); 
Where Eh is the hepatic extraction ratio 
 
Besides methodological constraints, any discrepancy in the insulin clearance data from the 
proposed hypothesis could also be due to the small number of women studied in each of the 
groups. Lack of significant differences could also be attributed to lack of power, owing to small 
sample size. Also, the study was conducted for a period of six months. Considering that 
contraception methods are used over a long period of time for their desired purpose, it may be 
more meaningful to study changes over a period longer than six months. It has been  
hypothesized that an inverse relationship exist between dietary carbohydrate to fat ratio and 
insulin clearance (36). Hence, type of diet could have an effect on insulin clearance, which was 
not controlled for in this study. It will be impractical to control study participants’ diet for the 
duration of the study.  
 
The purported study is significant as it provided information on total insulin clearance in lean vs. 
obese women after six months of COC use, and addressed another potential mechanism of 
 
 
40 
 
hyperinsulinemia in COC users. The study also provided insights on the effect of insulin 
clearance among African-American obese vs. non African-American obese women.  
 
The choice of COC formulation is important as excessive estrogenic activity is known to cause 
untoward thromboembolic effects, while progestins are known to have a deleterious effect on 
carbohydrate metabolism. Overall, the pilot study showed no differential effect on insulin 
clearance in lean vs. obese women after six months of COC use [Ortho Tri Cyclen; containing 
ethinyl estradiol 35mcg and norgestimate0.18/ 0.215/0.25 mg]. The study may suggest that 
norgestimate has minimal effect on insulin clearance, in contrast to previous studies using other 
progestins.  
 
Given that insulin clearance does not seem to be affected by the COC used in this study, future 
work on hyperinsulinemia as a result of contemporary COC use should focus on mechanisms for 
increased pancreatic insulin secretion and/or insulin resistance, and the effects of exogenous 
hormones on these processes.   
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